BASEL, 18-Jul-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Avastin, carcinoma, FDA, Roche, Sandra Horning, TECENTRIQ, treatment
Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison BASEL, 19-Apr-2018 — /EuropaWire/ — Roche … Read the full press release
Posted in Healthcare, Netherlands, Pharma & Biotech, Switzerland
Tagged Breakthrough Therapy, haemophilia, Hemlibra, inhibitors, medicines, Roche, Sandra Horning MD
BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged atezolizumab, Cancer, chemotherapy, lung, lung cancer, lungcancer, Roche, Sandra Horning, squamous
DUBLIN, 16-Jan-2018 — /EuropaWire/ — At Shire, we’ve been committed to the hemophilia community and the lives of every patient afflicted with this disease for more than 70 years. We are very proud of this legacy and take our role as … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech
Tagged Chugai, Genentech, Hemlibra, hemophilia, Howard Mayer M.D., IP, patent, rare diseases, Roche, Shire
Roche to acquire Ignyta for US$ 27.00 per share Ignyta’s investigational medicine entrectinib, a selective CNS-active tyrosine-kinase inhibitor being developed for tumours that harbor ROS1 or NTRK fusions, to expand Roche’s portfolio of oncology medicines BASEL, 27-Dec-2017 — /EuropaWire/ — … Read the full press release
Posted in Business, Pharma & Biotech, Switzerland, Technology
Tagged Daniel O’Day, Ignyta, Roche
New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be associated with a reduction of multiple … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Esbriet, idiopathic pulmonary fibrosis, nintedanib, respiratory diseases, Roche, Sandra Horning MD
BASEL, 14-Sep-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people with … Read the full press release
Posted in Healthcare, Pharma & Biotech, Sweden
Tagged BRIM8, melanoma, phase III BRIM8 study, Roche, Sandra Horning MD
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Haemophilia A, NEJM, Roche, Roche's HAVEN 1, Sandra Horning MD, The New England Journal of Medicine
First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of Health (NIH)-funded collaborative group study BASEL, 24-Apr-2017 — /EuropaWire/ — Roche (SIX: … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Lucentis®, MD, Roche, Sandra Horning, treat diabetic retinopathy
First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy BASEL, 24-Apr-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged bladder cancer, FDA, Roche, Sandra Horning MD, TECENTRIQ
Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis BASEL, 24-Apr-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged American Academy of Neurology Annual Meeting, neuroscience, OCREVUS, Roche, Sandra Horning
New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy to Rituxan/ MabThera (rituximab) plus chemotherapy in previously untreated follicular lymphoma will be presented in the Plenary Scientific Session New results for Venclexta/Venclyxto(venetoclax) and investigational medicine … Read the full press release
15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra/RoActemra data from GiACTA – the largest ever clinical trial in people with giant cell arteritis (GCA), a condition for which there has been no approved therapy … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged 2016 ACR/ARHP, Actemra®/RoActemra®, Rituxan®/MabThera®, Roche, Sandra Horning MD
OCREVUS is the first investigational medicine seeking marketing authorisation for both relapsing and primary progressive multiple sclerosis (MS) FDA grants Priority Review Designation for OCREVUS Biologics License Application (BLA) BASEL, 29-Jun-2016 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged EMA, FDA, OCREVUS, Roche, Sandra Horning M.D.
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product’s label Sandoz’ submission includes data from multiple clinical trials with over 800 patients … Read the full press release
Posted in European Union, Germany, Healthcare, Pharma & Biotech, Switzerland
Tagged European Medicines Agency, MabThera®, Roche, Sandoz
19 Roche medicines are included in more than 200 abstracts during ASCO 2016 New results for cancer immunotherapy atezolizumab in bladder cancer and other cancer types Early results for atezolizumab in combination with targeted medicines and the investigational cancer immunotherapy … Read the full press release
In the pivotal study, treatment with Gazyvaro plus bendamustine chemotherapy reduced the risk of disease worsening or death by 52 percent compared to bendamustine alone BASEL, 04-May-2016 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU … Read the full press release
cobas 6800/8800 Systems offer fastest time to results and highest throughput of any molecular platform, helping to improve disease management and patient care BASEL, 19-10-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged cobas®, cobas® HBV, FDA approval, HCV viral load tests, Roche
BASEL, 12-8-2015 — /EuropaWire/ — Today (11 August 2015), Roche welcomed 100 European university students from 34 countries studying science and art to the Salzburg Festival, the world’s largest and most prestigious festival of music and drama. The annual Roche … Read the full press release
Posted in Art & Culture, Entertainment, Science, Switzerland
Tagged art, European university students, Roche, Salzburg Festival, science
The Perjeta regimen is the first neoadjuvant (pre-surgery) breast cancer treatment recommended for approval in the EU based on the benefit in achieving pathological complete response (pCR) BASEL, 29-6-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged CHMP, Perjeta, pre-surgery breast cancer treatment, Roche, Sandra Horning
The Roche test enables healthcare professionals to identify patients with a suspected heart attack in the pre-hospital setting, helping ensure correct diagnosis and immediate, appropriate intervention. BASEL, 29-6-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that … Read the full press release
40 data presentations across 7 autoimmune conditions, including new results from RoACTEMRA in early RA and systemic sclerosis (SSc) – a potentially fatal disease with limited treatment options¹ BASEL, 29-5-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today … Read the full press release
Second FDA Breakthrough Therapy Designation for MPDL3280A following bladder cancer in 2014 BASEL, 3-2-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received a second Breakthrough Therapy Designation from the United States Food and … Read the full press release
BASEL, 3-2-2015 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for up to 15,604,288 outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of … Read the full press release
Posted in Business, Financial, Healthcare, Management, Pharma & Biotech, Switzerland
Tagged cash tender offer, Foundation Medicine, Inc., Roche, shares of common stock
BASEL, 12-1-2015 — /EuropaWire/ — Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer Roche to acquire a majority interest in Foundation Medicine (FMI) of up to 56.3% on a fully diluted basis … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, Sweden
Tagged Daniel O’Day, Foundation Medicine, Inc., Michael J. Pellini, Roche
BASEL, 3-12-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the acquisition of Ariosa Diagnostics, Inc. (Ariosa), a privately-held company based in San Jose, California, USA. Ariosa is a molecular diagnostics testing service provider that provides a … Read the full press release
Posted in Business, Healthcare, Management, Pharma & Biotech, Switzerland, Technology
Tagged Ariosa Diagnostics, cell-free DNA (cfDNA) technology, CLIA laboratory, Inc., Ken Song MD, molecular diagnostics testing service provider, non-invasive prenatal testing (NIPT) service, Roche, Roland Diggelmann
First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer BASEL, 13-8-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EU) approved the … Read the full press release
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib BASEL, 11-7-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved … Read the full press release
Basel, 04-6-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA. Genia is developing a single-molecule, semiconductor based, DNA sequencing platform using nanopore … Read the full press release
Posted in Business, Management, Pharma & Biotech, Switzerland, Technology
Tagged Basel, Genia Technologies, nanopore technology, Roche, Roland Diggelmann, Stefan Roever
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older Basel, 29-4-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that … Read the full press release
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received approval from … Read the full press release
Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Basel, biologic medicines, Daniel O’Day, Germany, Kadcyla, licensed biologics, Oceanside, Penzberg, Perjeta, pertuzumab, RoACTEMRA, Roche, Switzerland, tocilizumab, trastuzumab emtansine, USA, Vacaville
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer 19-7-2013 — /europawire.eu/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) … Read the full press release
New test expands cancer diagnostics portfolio and strengthens Roche Diagnostics’ comprehensive tumour marker menu 19-7-2013 — /europawire.eu/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch (except US) of Elecsys ProGRP, a test that distinguishes between the two … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Cancer, cancer diagnosis, lung cancer, non-small cell, NSCLC, ProGRP test, Roche, SCLC, small cell
Tests support long-term routine management of organ transplant recipients and enhanced workflow in medical labs 19-7-2013 — /europawire.eu/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
